NCT04895748 2026-03-03DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other MalignanciesNovartisPhase 1 Terminated40 enrolled
NCT04152018 2025-05-28Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.PfizerPhase 1 Terminated85 enrolled
NCT03549000 2024-12-13A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.NovartisPhase 1 Terminated127 enrolled
NCT02890069 2023-01-11A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatNovartisPhase 1 Completed298 enrolled
NCT04060342 2022-08-18GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaGossamer Bio Inc.Phase 1 Terminated61 enrolled